Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
The Journal of Biological Chemistry|October 5, 2006
Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1CDaniel M Dupont, Grant E Blouse, Martin Hansen, et al.
Inflammatory Bowel Diseases|January 25, 2022
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With VedolizumabDino Tarabar, Katia El Jurdi, Cindy Traboulsi, et al.
Thrombosis Research|January 4, 2011
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial diseaseEmile L E de Bruijne, Ann Gils, Dingeman C Rijken, et al.
Journal of Crohn'S & Colitis|March 30, 2016
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to InfliximabKonstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 31, 2002
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependentLaetitia Devy, Silvia Blacher, Christine Grignet-Debrus, et al.
The AAPS Journal|September 8, 2016
Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®Joseph C Marini, Jocelyn Sendecki, Freddy Cornillie, et al.
The FEBS Journal|November 11, 2005
His374 of wheat endoxylanase inhibitor TAXI-I stabilizes complex formation with glycoside hydrolase family 11 endoxylanasesKatleen Fierens, Ann Gils, Stefaan Sansen, et al.
Analytical Chemistry|August 5, 2016
Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISAKaren Leirs, Phalguni Tewari Kumar, Deborah Decrop, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2019
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's DiseaseErwin Dreesen, Filip Baert, David Laharie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2014
A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitisMaria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
The Journal of Biological Chemistry|October 5, 2006
Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1CDaniel M Dupont, Grant E Blouse, Martin Hansen, et al.
Inflammatory Bowel Diseases|January 25, 2022
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With VedolizumabDino Tarabar, Katia El Jurdi, Cindy Traboulsi, et al.
Thrombosis Research|January 4, 2011
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial diseaseEmile L E de Bruijne, Ann Gils, Dingeman C Rijken, et al.
Journal of Crohn'S & Colitis|March 30, 2016
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to InfliximabKonstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 31, 2002
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependentLaetitia Devy, Silvia Blacher, Christine Grignet-Debrus, et al.
The AAPS Journal|September 8, 2016
Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®Joseph C Marini, Jocelyn Sendecki, Freddy Cornillie, et al.
The FEBS Journal|November 11, 2005
His374 of wheat endoxylanase inhibitor TAXI-I stabilizes complex formation with glycoside hydrolase family 11 endoxylanasesKatleen Fierens, Ann Gils, Stefaan Sansen, et al.
Analytical Chemistry|August 5, 2016
Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISAKaren Leirs, Phalguni Tewari Kumar, Deborah Decrop, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2019
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's DiseaseErwin Dreesen, Filip Baert, David Laharie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2014
A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitisMaria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, et al.
Pageof 17